A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment

Inclusion Criteria:

- Screening laboratory result indicating Hepatitis C Virus (HCV) Genotype (GT) 1, 2, 3,
4, 5 or 6 infection. Mixed GT and indeterminate GT may be acceptable.

- A negative hepatitis B surface antigen (HBsAg), and negative anti-hepatitis B core
(HBc) or; hepatitis B virus (HBV) deoxyribonucleic acid (DNA) less than the lower
limit of quantification (LLOQ) in participants with isolated positive anti-HBc. (For
sites participating in Bulgaria, France, Germany, Poland, Russia, Spain, and UK)

- Does not have current active HBV infection defined as positive HBsAg or HBV DNA
greater than or equal to LLOQ in subjects with isolated positive anti-HBc (i.e
negative HBsAg and anti-HBs. (For sites in United States, Puerto Rico, and Canada)

- Positive plasma HCV antibody and HCV ribonucleic acid (RNA) viral load greater than or
equal to 1000 IU/mL at Screening.

- Aspartate aminotransferase to Platelet Ratio Index (APRI) score of less than or equal
to 1, at time of screening.

- Treatment-naive to any approved or investigational anti-HCV medication.

Exclusion Criteria:

- Female participant who is pregnant, breastfeeding or is considering becoming pregnant
during the study, or for approximately 30 days after the last dose of study drug.

- Any current or historical clinical evidence of decompensated cirrhosis.

- History of hepatocellular carcinoma (HCC).